Assessment of the Effects of the Specific Endothelin-A Antagonist ZD4054 on Prostate Cancer Biomarkers in Patients With Castrate-resistant Metastatic Disease.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Zibotentan (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 05 Aug 2010 New trial record